Severe acute respiratory syndrome coronavirus-2 (SAR-CoV-2) causes coronavirus disease 2019 (COVID19) that is responsible for short and long-term disease, as well as death, in susceptible hosts. The receptor binding domain (RBD) of the SARS-CoV-2 Spike (S) protein binds to cell surface angiotensin converting enzyme type-II (ACE2) to initiate viral attachment and ultimately viral pathogenesis. The SARS-CoV-2 S RBD is a major target of neutralizing antibodies (NAbs) that block RBD – ACE2 interactions. In this report, NAb-RBD binding epitopes in the protein databank were classified as C1, C1D, C2, C3, or C4, using a RBD binding profile (BP), based on NAb-specific RBD buried surface area and used to predict the binding epitopes of a series of uncharacterized NAbs. Naturally occurring SARS-CoV-2 RBD sequence variation was also quantified to predict NAb binding sensitivities to the RBD-variants. NAb and ACE2 binding studies confirmed the NAb classifications and determined whether the RBD variants enhanced ACE2 binding to promote viral infectivity, and/or disrupted NAb binding to evade the host immune response. Of 9 single RBD mutants evaluated, K417T, E484K, and N501Y disrupted binding of 65% of the NAbs evaluated, consistent with the assignment of the SARS-CoV-2 P.1 Japan/Brazil strain as a variant of concern (VoC). RBD variants E484K and N501Y exhibited ACE2 binding equivalent to a Wuhan-1 reference SARS-CoV-2 RBD. While slightly less disruptive to NAb binding, L452R enhanced ACE2 binding affinity. Thus, the L452R mutant, associated with the SARS-CoV-2 California VoC (B.1.427/B.1.429-California), has evolved to enhance ACE2 binding, while simultaneously disrupting C1 and C2 NAb classes. The analysis also identified a non-overlapping antibody pair (1213H7 and 1215D1) that bound to all SARS-CoV-2 RBD variants evaluated, representing an excellent therapeutic option for treatment of SARS-CoV-2 WT and VoC strains.
【저자키워드】 SARS-CoV-2, Neutralizing antibodies, variant of concern, RBD, epitope mapping, ACE2 binding affinity, 【초록키워드】 Treatment, coronavirus disease, neutralizing antibody, Coronavirus disease 2019, ACE2, COVID19, SAR-CoV-2, Neutralizing antibodies, spike, antibody, viral pathogenesis, variant, severe acute respiratory syndrome coronavirus-2, severe acute respiratory syndrome Coronavirus, angiotensin converting enzyme, binding affinity, Receptor binding domain, Severe acute respiratory syndrome, Protein, sensitivity, Epitopes, Viral, Host immune response, viral infectivity, L452R, N501Y, P.1, death, E484K, mutant, respiratory, disease, Strains, predict, interactions, NAb, binding, SARS-CoV-2 spike, Coronavirus-2, Analysis, angiotensin, ACE2 binding, SARS-CoV-2 RBD, therapeutic option, surface area, susceptible hosts, acute respiratory syndrome, acute respiratory syndrome coronavirus, enzyme, NAbs, RBD binding, hosts, SARS-CoV-2 S, RBD variants, sequence variation, while, SARS-CoV-2 WT, susceptible, Cell, Wuhan-1, ENhance, bind, responsible, evaluated, exhibited, less, promote, the RBD, cause, representing, evade, disrupting, Naturally, quantified, binding epitope, C1D, RBD variant, the SARS-CoV-2, 【제목키워드】 classification, concern, property, Against,